These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. Salas MQ; Prem S; Atenafu EG; Law AD; Lam W; Al-Shaibani Z; Loach D; Kim DDH; Michelis FV; Lipton JH; Kumar R; Mattsson J; Viswabandya A Eur J Haematol; 2019 Nov; 103(5):510-518. PubMed ID: 31449699 [TBL] [Abstract][Full Text] [Related]
10. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Yang J; Jiang J; Cai Y; Li S; Wan L; Zhu J; Liu H; Shao S; Bai H; Wang C; Song X Bone Marrow Transplant; 2019 Jul; 54(7):1049-1057. PubMed ID: 30446741 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience. Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087 [TBL] [Abstract][Full Text] [Related]
16. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation. Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839 [TBL] [Abstract][Full Text] [Related]
17. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500 [TBL] [Abstract][Full Text] [Related]
18. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial. Zu Y; Li Z; Gui R; Liu Y; Zhang Y; Yu F; Zhao H; Fu Y; Zhan X; Wang Z; Xing P; Wang X; Wang H; Zhou J; Song Y Bone Marrow Transplant; 2022 Oct; 57(10):1573-1580. PubMed ID: 35840747 [TBL] [Abstract][Full Text] [Related]
19. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646 [TBL] [Abstract][Full Text] [Related]
20. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC. Bailén R; Pascual-Cascón MJ; Guerreiro M; López-Corral L; Chinea A; Bermúdez A; Sampol A; Heras I; García-Torres E; Torres M; Roca JR; Herruzo B; Sanz J; Fonseca M; Herrera P; Colorado M; Bento L; López-Godino O; Martín-Calvo C; Fernández-Caldas P; Marcos-Jubilar M; Sánchez-Ortega I; Solano C; Noriega V; Humala K; Oarbeascoa G; Díez-Martín JL; Kwon M; Transplant Cell Ther; 2022 Apr; 28(4):204.e1-204.e10. PubMed ID: 35108627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]